Saltar al contenido
MilliporeSigma

Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology (1999-08-19)
J Berwaerts, J Verhelst, C Mahler, R Abs
RESUMEN

We report on a 30-year-old female with a pituitary-dependent Cushing's disease, who refused transsphenoidal surgery and was treated with ketoconazole and cabergoline. After approximately 3 years of therapy, the patient herself decided, without the knowledge of her treating physician, to interrupt contraception. As the patient became pregnant she ceased the intake of all medication (between the third and seventh week), but resumed it soon after pregnancy was diagnosed because of relapsing clinical signs. Pregnancy and vaginal delivery at 37 weeks gestation passed uneventfully. The newborn male infant did not demonstrate any congenital malformations and was normally sexually developed. With reference to this case, we discuss the difficulties in the medical treatment of Cushing's syndrome during pregnancy. Whereas outside pregnancy only efficacy and side-effects are taken into account, teratogenicity is an important question in these patients. Experience with different drugs is listed. This is only the second time that ketoconazole has been used during pregnancy for the treatment of Cushing's syndrome. We argue that ketoconazole may be safe as well as effective in pregnancy and, furthermore, without any consequences for the child.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Ketoconazole, 99.0-101.0% (EP, titration)
USP
Ketoconazole, United States Pharmacopeia (USP) Reference Standard
Supelco
Ketoconazole, Pharmaceutical Secondary Standard; Certified Reference Material
Ketoconazole, European Pharmacopoeia (EP) Reference Standard